(Q59340082)

12 March 2019

14 March 2019

21 March 2019

24 March 2019

22 April 2019

25 April 2019

17 June 2019

25 June 2019

12 September 2019

10 October 2019

on focus list of Wikimedia project

15 July 2021

ScienceSource

0 references

exact match

https://scigraph.springernature.com/pub.10.1186/s13052-018-0563-0

0 references

cites work

Nasal route for direct delivery of solutes to the central nervous system: fact or fiction?

1 reference

12 December 2020

New advances in the transport of doxorubicin through the blood-brain barrier by a peptide vector-mediated strategy.

1 reference

12 December 2020

Enzyme-replacement therapy in mucopolysaccharidosis I.

1 reference

12 December 2020

Brain drug targeting and gene technologies

1 reference

12 December 2020

Drug and gene targeting to the brain with molecular Trojan horses

1 reference

12 December 2020

Long-term normalization in the central nervous system, ocular manifestations, and skeletal deformities by a single systemic adenovirus injection into neonatal mice with mucopolysaccharidosis VII.

1 reference

12 December 2020

ABC transporters and the blood-brain barrier

1 reference

12 December 2020

The blood-brain barrier: bottleneck in brain drug development

1 reference

12 December 2020

CNS-directed gene therapy for lysosomal storage diseases

1 reference

12 December 2020

Lysosomal storage diseases and the blood-brain barrier

1 reference

12 December 2020

Structure and function of the blood-brain barrier

1 reference

12 December 2020

Cell- and gene-based therapeutic approaches for neurological deficits in mucopolysaccharidoses

1 reference

12 December 2020

Intrathecal enzyme replacement therapy for mucopolysaccharidosis I: translating success in animal models to patients

1 reference

12 December 2020

Reengineering biopharmaceuticals for targeted delivery across the blood-brain barrier

1 reference

12 December 2020

Gene therapy approaches for lysosomal storage disorders, a good model for the treatment of mendelian diseases

1 reference

12 December 2020

Immunologic privilege in the central nervous system and the blood-brain barrier

1 reference

12 December 2020

Potential use of polymeric nanoparticles for drug delivery across the blood-brain barrier

1 reference

12 December 2020

Mucopolysaccharidoses and other lysosomal storage diseases

1 reference

12 December 2020

Transporters at CNS barrier sites: obstacles or opportunities for drug delivery?

1 reference

12 December 2020

Development of nanoparticle-bound arylsulfatase B for enzyme replacement therapy of mucopolysaccharidosis VI.

1 reference

12 December 2020

Insight on the fate of CNS-targeted nanoparticles. Part I: Rab5-dependent cell-specific uptake and distribution.

1 reference

12 December 2020

Current approaches to enhance CNS delivery of drugs across the brain barriers

1 reference

12 December 2020

Pathways for small molecule delivery to the central nervous system across the blood-brain barrier

1 reference

12 December 2020

Challenges associated with Penetration of Nanoparticles across Cell and Tissue Barriers: A Review of Current Status and Future Prospects

1 reference

12 December 2020

Blood-brain barrier drug delivery of IgG fusion proteins with a transferrin receptor monoclonal antibody

1 reference

12 December 2020

Laronidase-functionalized multiple-wall lipid-core nanocapsules: promising formulation for a more effective treatment of mucopolysaccharidosis type I.

1 reference

12 December 2020

Transcytosis of macromolecules at the blood-brain barrier.

1 reference

12 December 2020

Gene therapy for neurologic manifestations of mucopolysaccharidoses

1 reference

12 December 2020

A phase I/II study of intrathecal idursulfase-IT in children with severe mucopolysaccharidosis II.

1 reference

12 December 2020

Neuronopathic lysosomal storage disorders: Approaches to treat the central nervous system

1 reference

12 December 2020

Endocytosis of Nanomedicines: The Case of Glycopeptide Engineered PLGA Nanoparticles.

1 reference

12 December 2020

Low-dose, continual enzyme delivery ameliorates some aspects of established brain disease in a mouse model of a childhood-onset neurodegenerative disorder.

1 reference

12 December 2020

Evolving Drug Delivery Strategies to Overcome the Blood Brain Barrier.

1 reference

12 December 2020

A phase 1/2 study of intrathecal heparan-N-sulfatase in patients with mucopolysaccharidosis IIIA.

1 reference

12 December 2020

Targeted Polymeric Nanoparticles for Brain Delivery of High Molecular Weight Molecules in Lysosomal Storage Disorders

1 reference

12 December 2020

Adeno-Associated Virus-Based Gene Therapy for CNS Diseases.

1 reference

12 December 2020

Brain Targeting in MPS-IIIA.

1 reference

12 December 2020

Intranasal Adeno-Associated Virus Mediated Gene Delivery and Expression of Human Iduronidase in the Central Nervous System: A Noninvasive and Effective Approach for Prevention of Neurologic Disease in Mucopolysaccharidosis Type I.

1 reference

12 December 2020